Home » Newsletters » BioWorld Science

BioWorld Science

May 18, 2009

View Archived Issues

Agile's low-dose levonorgestrel/ethinylestradiol contraceptive patch shows safety and efficacy

Positive clinical results reported for Archimedes' NasalFent fentanyl nasal spray for cancer pain

Novel c-Met and Ron kinase inhibitor, MK-8033, shows antitumor activity in preclinical studies

Clofarabine prodrug active in various tumor models

Heat shock protein 90 inhibitor CUDC-305 shows potent and lasting in vivo antitumor activity

Boehringer and DeveloGen sign agreement in diabetes, obesity and the metabolic syndrome

Bayer Schering launches oral contraceptive Qlaira in Europe

FDA approves Novartis' Prevacid 24HR for frequent heartburn

Allergan claims novel sphingosine 1-phosphate receptor ligands for the treatment of pain

Cardioxyl Pharmaceuticals and Johns Hopkins University claim novel compounds for heart failure

Boehringer Ingelheim reports discovery of chemokine CCR10 receptor antagonists as antipsoriatics

Polo-like kinase 1 inhibitors for cancer treatment presented by Nerviano Medical Sciences

CMV DNA vaccine may control post-transplant CMV viremia; interim phase II data disclosed

ImmuneRegen and University of Pittsburgh sign agreement for influenza drug Viprovex

FDA approves ActoGeniX's IND for phase Ib clinical trial of AG-013 in oral mucositis

DCGI grants approval to Piramal Life to initiate two phase I/II studies of cancer drug P-276

Oxygen Biotherapeutics signs LP-CRADA with NMRC and WRAIR for Oxycyte

Amgen presents Q1 product and pipeline update

Ablynx receives orphan drug designation and provides pipeline update

Intravitreal IBI-20089 reduces retinal thickness in cystoid macular edema patients in phase I trial

AGI releases results from phase III Rezular trial, plans to cease development in IBS-D

Nonsteroidal antiandrogen shows efficacy in castration-resistant prostate cancer in phase I/II trial

Antares presents preliminary phase II transdermal contraception results

Metabolic Solutions presents preliminary results from phase IIa MSDC-0160 trial

Novavax completes enrollment in second phase II seasonal influenza vaccine trial

Data show cardiovascular therapeutic potential for two Compugen peptides

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...